$BNTC News
Last published 2w ago
- 2w agoBNTCBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301GlobeNewswire- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across
- 1mo agoBNTCBNTCWLonza AG - 1773841 - Lonza AGEarnings Call TranscriptsSo hello everyone and thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibault Boutrin. I'm part of the European Pharma Equity Research Team based in London. Before we start th
- 1mo agoBNTCBenitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational UpdateGlobeNewswireAll six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C
- 6mo agoBNTCBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational UpdateGlobeNewswireLate-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months
- 6mo agoBNTCBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1
- 6mo agoBNTCPRTCPureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of DirectorsBusiness WirePureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that
- 6mo agoBNTCSeaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of DirectorsBusiness WireDr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson Seaport Therapeutics ("Seaport" or the "Company"),
- 8mo agoBNTCBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)GlobeNewswireHAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 8mo agoBNTCBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewswire- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD
- 8mo agoBNTCBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewswire-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and
- 9mo agoBNTCBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational UpdateGlobeNewswire-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month
- 10mo agoBNTCBenitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of ResponseGlobeNewswire• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements
- 12mo agoBNTCBenitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational UpdateGlobeNewswire–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for
- 1y agoBNTCBenitec Biopharma Inc. Announces Pricing of $100 Million Common Stock OfferingGlobeNewswireHAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma Inc. Announces Proposed Public OfferingGlobeNewswireHAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301GlobeNewswireFast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted
- 1y agoBNTCBenitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of DirectorsGlobeNewswireHAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 1y agoBNTCBenitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular DystrophyGlobeNewswireHAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational UpdateGlobeNewswireInterim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025
- 1y agoBNTCBenitec Biopharma Releases Third Quarter 2025 Financial ResultsGlobeNewswireHAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on
- 1y agoBNTCBenitec Biopharma Inc. Announces Pricing of $30 Million Common Stock OfferingGlobeNewswireHAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewswire-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months
- 1y agoBNTCBenitec Biopharma to Participate in Upcoming Conferences in MarchGlobeNewswireHAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewswire-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association
- 1y agoBNTCBenitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific ConferenceGlobeNewswireHAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 1y agoBNTCBenitec Biopharma to Participate in Upcoming Conferences in January and FebruaryGlobeNewswireHAYWARD, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma to Participate in Upcoming Investor Conferences in DecemberGlobeNewswireHAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 1y agoBNTCBenitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewswire-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study
- 2y agoBNTCBenitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare ConferenceGlobeNewswireHAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 2y agoBNTCBenitec Biopharma Announces Updated Investor Webcast InformationGlobeNewswire-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the
- 2y agoBNTCBenitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle SocietyGlobeNewswire-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score
- 2y agoBNTCBenitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateGlobeNewswire-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and
- 2y agoBNTCBenitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle SocietyGlobeNewswireHAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 2y agoBNTCBenitec Biopharma CEO to Participate in OPMD Awareness Day WebinarGlobeNewswireHAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 2y agoBNTCBenitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a StudyGlobeNewswire-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose
- 2y agoBHVNBNTCBenitec Biopharma Announces Appointment of Kishen Mehta to its Board of DirectorsGlobeNewswireHAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 2y agoBNTCBenitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD Subject was Safely
- 2y agoBNTCBenitec Biopharma to Participate in the Citizens JMP Life Science ConferenceGlobeNewswireHAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 2y agoBNTCBenitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyGlobeNewswire-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements across multiple
- 2y agoBNTCBenitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionGlobeNewswireHAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 2y agoBNTCBenitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024GlobeNewswireHAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 2y agoBNTCBenitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject
- 2y agoBNTCBenitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyGlobeNewswireHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 2y agoBNTCBenitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare ConferenceGlobeNewswireHAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 2y agoBNTCBenitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswireHAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 3y agoBNTCBenitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational UpdateGlobeNewswireReceived FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History
- 3y agoBNTCBenitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public OfferingGlobeNewswireHAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 3y agoBNTCBenitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public OfferingGlobeNewswireHAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
- 3y agoBNTCBenitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023GlobeNewswireHAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
- 3y agoBNTCBenitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyGlobeNewswireHAYWARD, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based